[冠状动脉慢性全闭和分叉病变,当代管理的经验教训:病例报告]
Carlos Esteban Uribe-Londoño1, Cristhian Felipe Ramirez-Ramos1,2,3, Gustavo Castilla-Agudelo3
1Departamento de Cardiología Intervencionista y Hemodinámica, Cardiovascular Clínica CardioVID. Medellín, Colombia. Departamento de Cardiología Intervencionista y Hemodinámica Cardiovascular Clínica CardioVID Medellín Colombia.
Archivos peruanos de cardiologia y cirugia cardiovascular
|January 25, 2024
概括
冠状动脉疾病带有慢性全闭和分叉病变带来了挑战. 本案例研究表明,治疗这些复杂病变的冠状动脉干预策略是成功的.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 血管医学 血管医学
背景情况:
- 冠状动脉疾病 (CAD) 涉及慢性全闭 (CTO) 和分叉病变,这对干预心脏病学家来说是一个重大挑战.
- 对于同时出现双叉病变的CTO,最佳的干预策略仍在争论中,这会影响治疗成功率.
研究的目的:
- 介绍一例冠状动脉干预成功的病例,该病例涉及患有慢性全封闭和分叉病变的患者.
- 突出一种管理复杂冠状动脉疾病情景的潜在方法.
主要方法:
- 冠状动脉动图进行,以诊断复杂的冠状动脉解剖.
- 通过皮肤冠状动脉干预 (PCI) 策略被用来解决CTO和双叉损伤.
主要成果:
- 冠状动脉干预成功地治疗了慢性总闭塞和相关的分叉病变.
- 通过这项干预,患者的胸痛得到了解决.
结论:
- 冠状动脉干预可以是一个可行的和成功的策略,用于管理复杂的病例的慢性总封闭与分叉病变.
- 对这种特定的患者亚组进行最佳技术的进一步研究是有必要的.
相关概念视频
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome V: Nursing Management
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


